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OBJECTIVES The study evaluated the incidence and predictors of creatine kinase–MB isoenzyme
(CK-MB) elevation after successful coronary intervention using current devices, and assessed
the influence on in-hospital course and midterm survival.
BACKGROUND The CK-MB elevation after coronary intervention predominantly using balloon angioplasty
correlates with late cardiac events of myocardial infarction (MI) and death. Whether CK-MB
elevation after nonballoon devices is associated with an adverse short and midterm prognosis
is unknown.
METHODS The incidence and predictors of CK-MB elevation after coronary intervention were
prospectively studied in 1,675 consecutive patients and were followed for in-hospital events
and survival.
RESULTS CK-MB elevation was detected in 313 patients (18.7%), with 1–33 in 12.8%, 3–53 in 3.5%
and .53 normal in 2.4% of patients. Procedural complications or electrocardiogram changes
occurred in only 49% of the CK-MB-elevation cases; CK-MB elevation was more common
after nonballoon devices (19.5% vs. 11.5% after percutaneous transluminal coronary angio-
plasty; p , 0.01). Predictors of CK-MB elevation on multivariate analysis were diffuse
coronary disease (p 5 0.02), systemic atherosclerosis (p 5 0.002), stent use (p 5 0.04) and
absence of beta-blocker therapy (p 5 0.001). Adverse in-hospital cardiac events were more
frequent in patients with .53 CK-MB elevation, with no significant difference between
1–53 CK-MB elevation versus normal CK-MB group. During a mean follow-up of 13 6 3
months, the incidence of death in the CK-MB-elevation group was 1.6% versus 1.3% in the
normal CK-MB group (p 5 NS).
CONCLUSIONS The CK-MB elevation after coronary intervention was observed even in the absence of
discernible procedural complications and was more common in patients with diffuse
atherosclerosis. In-hospital clinical events requiring prolonged monitoring were higher in
.53 CK-MB-elevation patients only. Midterm survival of CK-MB-elevation patients was
similar to those with normal CK-MB. Our prospective analysis shows a lack of adverse
in-hospital cardiac events and suggests that early discharge of stable 1–53 normal CK-MB-
elevation patients after successful coronary intervention is safe. (J Am Coll Cardiol 1999;34:
663–71) © 1999 by the American College of Cardiology
Elevation of creatine kinase–MB isoenzyme (CK-MB) has
been shown to occur after 6% to 30% of otherwise successful
percutaneous coronary interventions (1–5). Recently, much
controversy has arisen regarding the postprocedure minor
CK-MB elevation, commonly called “infarctlets,” and its
clinical relevance on short- and long-term prognosis after
See page 672
interventions. Numerous earlier reports, mostly involving
percutaneous transluminal coronary angioplasty (PTCA),
have demonstrated that elevation of CK-MB is associated
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not only with a higher mortality but also with a higher risk
of subsequent cardiac events and higher cost (5–10). In
these studies, the risk of adverse outcome increased propor-
tional to the magnitude of CK-MB elevation. Recent trials
involving newer devices have revealed higher incidence of
CK-MB elevation postprocedure but a lack of correlation
with midterm adverse cardiac events and survival (11–13). It
is possible that a stable and larger postprocedure lumen,
attained after successful new device intervention with a
lower target lesion revascularization (TLR), primarily de-
termines subsequent cardiac events, and the influence of
CK-MB elevation is overshadowed in the overall outcome.
Several experimental studies have identified the patho-
logic substrate for CK-MB release from the myocardium,
which is either myocardial necrosis or profound ischemic
injury but retention of cell viability (14,15). The causes of
CK-MB elevation postprocedure are multifactorial and
include transient vessel closure, slow flow, distal thrombo-
embolism, side branch closure, hypotension and prolonged
ischemia caused by longer balloon inflations (16–20).
Moreover, it is unclear whether CK-MB elevation after a
successful procedure is a reflection of the procedure itself or
a marker of diffuse atherosclerosis involving the vessel
(5,9,10). The present prospective study was conducted with
the following objectives: 1) to evaluate the incidence of
CK-MB elevation after various coronary interventional
devices, 2) to identify the clinical, angiographic and proce-
dural predictors of CK-MB elevation, 3) to assess in-
hospital course for any adverse cardiac events, 4) to evaluate
the safety of early postprocedure discharge of clinically
stable patients despite elevated CK-MB levels and 5) to
evaluate if CK-MB elevation has an effect on midterm (’12
months) survival.
METHODS
Patients. All patients undergoing percutaneous coronary
interventions at Mount Sinai Hospital, New York, between
January 1997 and February 1998 were included in the study.
Patients who had coronary intervention within 24 h of acute
myocardial infarction (MI) (n 5 82), urokinase infusion
(n 5 8), elevated preprocedure CK-MB (n 5 16) and
incomplete CK-MB values (n 5 32) were excluded from the
analysis. Patients with major complications occurring in the
catheterization laboratory including emergency coronary
artery bypass grafting (CABG) or death were also excluded
(n 5 8). The study population consisted of 1,675 consecu-
tive patients with preprocedure, 6 to 8 h and 16 to 24 h
postprocedure CK-MB values available for analysis. After
coronary intervention, patients were admitted either to the
coronary care unit or postprocedure telemetry care unit. If
the second postprocedure CK-MB was elevated, values were
further monitored (every 4 to 6 h) until levels declined.
Protocol. All patients had blood drawn for CK-MB mea-
surement and lipid profile at the time of femoral sheath
insertion and had a baseline 12-lead electrocardiogram
(ECG) within 24 h before the procedure. During the
interventional procedure, two noncontiguous ECG leads
were continuously monitored for heart rate and ST-T wave
changes. Continuous hemodynamic monitoring was done
by displaying the arterial line pressure. Interventional pro-
cedures were carried out in a standard fashion, and proce-
dural complications such as coronary spasm, arterial dissec-
tion, thromboembolism, transient vessel closure, abrupt
closure, slow flow, side branch closure, prolonged hypoten-
sion (systolic blood pressure ,80 mm Hg lasting for
.5 min), prolonged balloon inflation (.5 min) and persis-
tent chest pain (.30 min postprocedure) were recorded.
Subsequently, blood samples were drawn at 6 to 8 h and
16 to 24 h after the procedure for cardiac enzymes, routine
chemistry and complete blood cell counts. A 12-lead ECG
was routinely recorded after the procedure and on the
following morning (for in-patients). In cases of an adverse
clinical outcome, recurrent postprocedure chest pain and
prolonged hospitalization, further blood tests were per-
formed and ECGs were recorded, as deemed clinically
necessary. All ECGs were independently analyzed for ST
segment and T-wave changes, and for the appearance of
new Q-waves. During the initial four months of the study
period, patients with elevated CK-MB values were moni-
tored in-hospital for cardiac events, and CK-MB was
serially measured every 6 to 8 h until CK-MB declined to
,16 units and only then were patients discharged. Subse-
quently, by observing a total lack of any adverse clinical
events while waiting for CK-MB to return to baseline in the
1–53 normal CK-MB-elevation group, the policy was
changed to discharge clinically stable patients with declining
yet elevated CK-MB values.
The Mass technique was used to measure CK-MB. Total
Abbreviations and Acronyms
ACC/AHA 5 American College of
Cardiology/American Heart Association
CABG 5 coronary artery bypass grafting
CCS 5 Canadian Cardiovascular Society
CHF 5 congestive heart failure
CK-MB 5 creatine kinase–MB isoenzyme
ECG 5 electrocardiogram
IAMP 5 intra-aortic balloon pump
LAD 5 left anterior descending artery
LVEF 5 left ventricular ejection fraction
MI 5 myocardial infarction
PRCA 5 percutaneous rotational coronary
atherectomy
PTCA 5 percutaneous transluminal coronary
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RCA 5 right coronary artery
SVG 5 saphenous vein graft
TIMI 5 thrombolysis in myocardial infarction
TLR 5 target lesion revascularization
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creatine kinase (CK) was measured by an Hitachi 747
analyzer, and CK-MB was measured by immunoinhibition
using a Johnson and Johnson Vitros 950 analyzer (Roches-
ter, New York). If the CK-MB was abnormal (absolute total
$16 units or $10% of total CK) then it was further
confirmed using enzyme mass immunoassay by Baxter
Stratus-2 analyzer. Final CK-MB values of mass immuno-
assay were used for the analysis.
Intervention. Most (98%) of the coronary interventional
procedures were performed via the femoral route, with 2%
done by radial and brachial approaches. All patients received
aspirin 325 mg orally and a 70–100-USP units/kg intrave-
nous bolus of heparin. The activated clotting time was
maintained between 250 to 350 s throughout the procedure
using periodic IV boluses of heparin with a trend toward
lower values if abciximab was used. A 6–10F guiding
catheter was used. The distribution of various devices for
coronary interventions were: PTCA 10.4%; PRCA (percu-
taneous rotational coronary atherectomy) 25.1%; stent
28.5%; PRCA 1 stent 31.9%; and other devices (directional
coronary atherectomy, transluminal extraction catheter or
Angiojet [Possis Medical Inc., Minneapolis, Minnesota]
alone or in combination of stent or PRCA) 4.1%. All
interventions were performed using conventional tech-
niques, and the selection of a device was left to the
operator’s discretion. Abciximab was used in 38.8% of the
cases, particularly in high-risk coronary interventions such
as multivessel intervention, staged procedure, presence of
thrombus, saphenous vein graft (SVG) lesion, American
College of Cardiology/American Heart Association (ACC/
AHA) type C lesion, ostial lesions, heavily calcified and
bifurcation lesions. In some cases, abciximab was used only
after procedural complications were noted. Postprocedure
sheath was removed 4 to 6 h after intervention except in
cases of recurrent chest pain or a planned staged procedure
the next day.
Coronary interventions were classified as single vessel if
the intervention was done in one coronary vessel distribu-
tion (including branches) or multivessel if the intervention
was done in two or more coronary vessel distributions.
Single-vessel intervention was done in 89% and multivessel
interventions in 11% of the cases. Of these interventions,
9% were performed in SVGs. In cases of multiple lesions,
patients were grouped in the most adverse lesion character-
istics. Lesion length was measured visually or by on-line
quantitative coronary analysis using a digital caliper. De-
tailed quantitative coronary analysis of reference vessel size
and pre- and postprocedure minimal lumen diameter using
the CMS-MEDIS system was performed in 44% of the
cases (21).
In-hospital course. All patients were monitored in-
hospital for recurrent chest pain, heart failure, arrhythmia
(atrial or ventricular), ECG changes, acute or subacute
closure and the need for repeat catheterization, repeat
intervention and in-hospital CABG. Clinically stable pa-
tients with normal CK-MB were discharged on the next
day, on aspirin only following nonstent device use and on
aspirin plus ticlopidine 250 mg twice daily for four weeks if
a stent was implanted. In the beginning, patients with
elevated CK-MB were discharged only when values de-
clined to ,16 units. After the initial four months of the
study period, patients with 1–53 normal CK-MB elevation
were discharged once levels started declining and were stable
clinically despite elevated CK-MB values.
Follow-up. All patients discharged from the hospital were
followed at 1, 6, 12 and 18 months by telephone contact to
the patient or private physician for adverse cardiac events
and survival. Repeat hospital admissions within a week of
discharge were monitored in both groups. The survival data
were cross-checked with the New York State interventional
database. The clinical follow-up was available in 99.0% of
the CK-MB elevation group and 98.9% of the normal
CK-MB group.
Definitions. CK-MB elevations: CK-MB ,16 units 5 no
elevation; CK-MB .16 units 5 any elevation; 16–48
units 5 1–33 normal; 49–80 units 5 3–53 normal; .80
units 5 53 normal. Low-to-medium-level CK-MB eleva-
tion: 1–33 normal and 3–53 normal CK-MB values. High
CK-MB elevation: .53 normal CK-MB value. Angio-
graphic success: ,50% diameter obstruction postprocedure
with $TIMI (Thrombolysis in Myocardial Infarction) II
flow at end of procedure. Major complications: Q-wave MI,
emergent CABG or in-hospital death. Clinical success:
angiographic success of at least one lesion and no major
complications. Focal coronary disease: single lesion
,20 mm in length in one or more vessels. Diffuse coronary
disease: lesion $20 mm in length or multiple single lesions
in one or more vessels. Acute closure: postprocedure out of
the cath lab occlusion of the treated vessel within 24 h. Stent
thrombosis: acute or subacute closure in the stented vessel
within four weeks after stent deployment. Slow flow: de-
layed distal clearance of the dye in the absence of proximal
dissection or spasm. Coronary dissection: coronary dissec-
tions were graded from A–F according to the NHLBI
classification, and dissection grades A–C were considered
minor and grades D–F were considered major. Coronary
spasm: focal or diffuse narrowing of vessel without any
evident coronary dissection. Side branch closure: ,TIMI
III flow in a side branch of .1.5 mm diameter with normal
flow preprocedure. ACC/AHA classification: modified
ACC/AHA classification grading lesions into A, B1, B2 or
C category. Calcification: readily apparent fluoroscopic
densities in the lesion or vessel. Systemic atherosclerosis:
defined as history of peripheral vascular, aortic or cerebro-
vascular disease.
Statistics. The data were entered in a Microsoft Excel
database and transferred to the statistical program StatView
4.1 for analysis. Results are expressed as mean value 6 SD
or n (%). Comparison between two groups was done using
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chi-square analysis and continuous variables using the two-
tailed Student t test. Statistical significance was defined at
the level of p , 0.05. Variables with a significance level of
p value of 0.1 or less in the univariate analysis were
considered for the inclusion in the multivariate regression
model. In the multiple logistic regression analysis, selection
of the variables was achieved in a stepwise fashion, and
results were reported as odds ratio (OR) and 95% confi-
dence interval (CI).
RESULTS
Of the 1,675 patients and 4,068 lesions, angiographic
success was attained in 94.5% of lesions and clinical success
in 96.3% cases, with a 0.72% incidence of major complica-
tions. Any CK-MB elevation was noted in 313 of 1,675
patients (18.7%), with 1–33 normal in 12.6%, 3–53
normal in 3.7% and .53 normal in 2.4% of patients. The
time to peak CK-MB release was 6 to 8 h in 69%, 16 to 24 h
in 23% and .24 h in 8% of cases.
Patient characteristics. Baseline clinical characteristics for
the normal and elevated CK-MB groups are presented in
Table 1. Mean age for the entire group was 65 6 13 years,
with 31.6% being women. Variables correlated with
CK-MB release on univariate analysis were as follows:
female gender (p 5 0.02); CCS (Canadian Cardiovascular
Society) angina class III–IV (p , 0.001); smoking history
(p 5 0.08); renal failure (p , 0.001); systemic atheroscle-
rosis (p , 0.001); multivessel disease (p 5 0.03); abciximab
use (p , 0.001); and absence of beta-blocker therapy (p ,
0.001). Other factors such as hypertension, hypercholester-
olemia, level of LDL cholesterol, diabetes mellitus, prior
MI, prior intervention, prior CABG, mean left ventricular
ejection fraction (LVEF), severe LV dysfunction (LVEF
,30%), congestive heart failure (CHF) and IABP (intra-
aortic balloon pump) use were not different between the two
groups.
Vessel location. The incidence of CK-MB elevation was
19.6% after left anterior descending artery (LAD) interven-
tion, 17.2% after circumflex intervention, 16.9% after right
Figure 1. CK-MB elevation in relation to single- or multivessel
intervention.
Table 1. Clinical Variables for CK-MB Elevation in 1,675 Patients
Clinical Characteristics
Incidence of
CK-MB1 (%)
Any CK-MB
Elevation
(n 5 313)
Normal CK-MB
(n 5 1,362) p Value
Age (yrs) 18.7 65 6 12 64 6 12 NS
Female (%) 21.8 116 (37) 414 (30) 0.02
Hypertension (%) 18.5 218 (70) 957 (70) NS
Hypercholesterolemia (%) 19.1 152 (48) 641 (47) NS
Smoking (%) 20.3 59 (19) 231 (17) 0.08
Diabetes mellitus (%) 17.0 71 (23) 346 (25) NS
CCS class III–IV (%) 26.6 163 (52) 449 (33) 0.001
Prior MI (%) 19.8 115 (37) 467 (34) NS
Prior intervention (%) 17.1 66 (21) 321 (24) NS
Prior CABG (%) 17.9 46 (15) 211 (15) NS
Renal failure (%) 33.3 23 (7) 46 (3) , 0.001
Systemic atherosclerosis (%) 26.8 51 (16) 139 (10) , 0.001
LVEF (%) 18.7 48 6 9.8 50 6 14.2 NS
CHF (%) 20.8 38 (12) 145 (11) 0.1
Multivessel disease (%) 22.0 119 (38) 432 (32) 0.03
Abciximab use (%) 24.5 159 (51) 491 (36) , 0.001
Beta-blocker therapy (%) 13.2 85 (27) 558 (41) , 0.001
IABP use (%) 25 13 (4) 39 (3) 0.1
CABG 5 coronary artery bypass grafting; CCS 5 Canadian Cardiovascular Society; CHF 5 congestive heart failure; IABP 5
intra-aortic balloon pump; LVEF 5 left ventricular ejection fraction; MI 5 myocardial infarction.
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coronary artery (RCA) intervention (p 5 NS; multiple
comparisons) and 25.8% after SVG intervention (p , 0.01
vs. native vessel intervention). The CK-MB release was not
different between single-vessel intervention versus multives-
sel intervention (18.2% vs. 22.2%; p 5 0.2). The magnitude
of CK-MB elevations after single- and multivessel inter-
vention is shown in Figure 1.
Lesion morphology. As shown in Figure 2 there was an
increase in CK-MB elevation in relation to lesion complex-
ity using the ACC/AHA classification (A lesion 7.2%; B1
lesion 11.7%; B2 lesion 19.1%; and C lesions 28.5%; p ,
0.001 by ANOVA analysis). The mean lesion length was
18.2 mm in the CK-MB elevation group versus 13.4 mm in
the normal CK-MB group (p , 0.001). Thrombotic lesions
had a higher CK-MB release compared with nonthrom-
botic lesion (22.4% vs. 18.2%; p 5 0.02). Other lesion
characteristics such as eccentricity, calcification, ostial, total
or subtotal occlusion and angulated lesions did not correlate
with CK-MB release. Mean reference vessel size was not
different between the two groups: 2.74 6 0.63 mm in the
CK-MB elevation group vs. 2.69 6 0.74 mm in the normal
CK-MB group. As shown in Figure 3, CK-MB release
strongly correlated with diffuse coronary disease; diffuse
disease had a CK-MB release of 24.5% versus 16.2% in focal
disease (p , 0.001). This relationship was true in subgroups
of single-vessel intervention (diffuse disease 24.1% vs. focal
disease 16.4%; p , 0.001) and multivessel intervention
(diffuse disease 29.8% vs. focal disease 15.8%; p 5 0.02).
Device type. The incidence of CK-MB elevation after
various interventional devices is shown in Figure 4. The
PTCA has a significantly lower incidence of CK-MB
release compared with nonballoon devices (11.5% vs. 19.5%;
p , 0.01). The PRCA alone has a slightly lower incidence
of CK-MB elevation compared to stent alone (16% vs.
20.5%; p 5 0.07). There was no statistically significant
difference in CK-MB elevation after PTCA versus PRCA
(11.5% vs. 16%; p 5 0.16).
Procedural complications. The occurrence of various ma-
jor and minor procedural complications in the CK-MB
elevated group is shown in Table 2. The most common
procedural complication associated with CK-MB elevation
was side branch closure (22.7%). The incidence of side
branch closure was higher in the stent-only group (16.3%)
as compared with the PRCA-only group (4.5%) or PRCA
and stent group (6.7%); p , 0.001 by ANOVA analysis.
Other minor complications were slow flow, abrupt closure,
distal thromboembolism, intimal dissection, prolonged hy-
potension and prolonged balloon inflation. Persistent chest
pain postprocedure was noted in 12.1% of cases. Minor or
major ECG changes postprocedure were noted in 47.9% of
patients with CK-MB elevation. In 32% of cases, more than
one procedural complication was identified. Despite analysis
of procedural complications, persistent chest pain and ECG
changes, CK-MB elevation could only be predicted in 49%
of cases. In the remaining 51% of cases, no apparent cause
for elevated CK-MB elevation could be identified. The
sensitivity for the prediction of CK-MB elevation by per-
Figure 2. CK-MB elevation in relation to ACC/AHA lesion type.
Figure 3. CK-MB elevation in relation to diffuse or focal coronary
disease.
Figure 4. CK-MB elevation in relation to interventional device
type. *p 5 0.01 for PTCA vs. non-balloon devices; **p 5 0.07 for
PRCA only vs. stent only.
667JACC Vol. 34, No. 3, 1999 Kini et al.
September 1999:663–71 CK-MB Elevation After Successful Coronary Angioplasty
sistent/recurrent chest pain was 28.6% and by ECG changes
was 63.6%.
Multivariate predictors of CK-MB elevation. On multi-
ple logistic regression analysis as shown in Table 3, CCS
angina class III–IV, multivessel disease, diffuse coronary
disease, systemic atherosclerosis, stent use and SVG inter-
vention remained significant independent predictors of
CK-MB release. Use of beta-blockers had a negative cor-
relation on CK-MB release. Other factors such as female
gender, diabetes mellitus, smoking, abciximab use, LAD
location and PRCA use did not correlate with CK-MB
elevation in our multivariate model.
Hospital course. In-hospital course of CK-MB elevation
group is shown in Table 4. The overall incidence of major
complications was 0.72%. In-hospital cardiac events were
clustered mostly in the .53 CK-MB elevation group (n 5
40) requiring prolonged postprocedure hospital stay. In this
group there was a significantly higher incidence of arrhyth-
mia (20.5%; p , 0.001), CHF (36%; p , 0.001), persistent
recurrent chest pain (60%; p , 0.001), repeat catheteriza-
tion (36%; p , 0.001) and repeat intervention (17.7%; p ,
0.001) compared with .1–53 normal CK-MB elevation
group. In 25 of these 40 patients, pre- and postprocedure
analysis of LV function was available, and mean decrease in
LVEF was 12 6 9% (p , 0.01), with ,5% decrease in 18
patients (64%). Patients with low-to-medium CK-MB
elevation (1–53 normal) had incidences of arrhythmia
(2%), CHF (7%), recurrent chest pain (9%), repeat cathe-
terization (8%) and repeat intervention (2%) similar to the
normal CK-MB group. There were no early clinical events
noted in patients waiting in-hospital for CK-MB levels to
return to normal in the low-to-medium CK-MB elevation
group. Repeat hospital admissions within one week from
discharge occurred in 5.1% of .53 CK-MB-elevation
patients, but were similar among 3–53 normal CK-MB
(1.7%), 1–33 normal CK-MB (1.9%) and normal CK-MB
(1.2%) group; p 5 NS.
Follow-up. During a mean follow-up of 13 6 3 months
(range 9 to 18 months), 5 deaths (4 cardiac, 1 noncardiac)
have occurred in the CK-MB elevation group (1.6%) at a
mean period of 212 days after discharge, as compared with
18 deaths (15 cardiac, 3 noncardiac) in the normal CK-MB
group (1.3%) at a mean period of 246 days from discharge.
This difference was not statistically significant (p 5 0.43).
There were three cardiac deaths (7.5%) in .53 normal
CK-MB group (p 5 0.01), one cardiac death (1.7%) in
3–53 normal CK-MB group and one noncardiac death
(0.5%) in 1–33 normal CK-MB group. The observed
incidence of death in .53 normal CK-MB group was
significantly higher as compared with other groups (p 5
0.016). There was a lower incidence of death in patients on
beta-blockers at the time of intervention versus those who
were not on beta-blocker therapy (0.78% vs. 1.74%; p 5
0.045).
Table 2. Procedural Complications in CK-MB Elevation and Normal CK-MB Group
Complications*
Any CK-MB
Elevation
(n 5 313)
Normal CK-MB
(n 5 1,362) p Value
Side branch closure (%) 71 (22.7) 94 (6.9) , 0.001
Slow flow/no reflow (%) 21 (6.7) 6 (0.4) , 0.001
Coronary spasm 5 (1.6) 11 (0.8) NS
Transient abrupt vessel closure (%) 14 (4.5) 8 (0.6) , 0.001
Distal thromboembolism (%) 7 (2.2) 6 (0.4) , 0.001
NHBLI dissection grade C–F (%) 9 (2.9) 15 (1.1) 0.01
Prolonged balloon inflation (%) 13 (4.2) 8 (0.6) , 0.001
Prolonged hypotension (%) 7 (2.2) 7 (0.5) , 0.002
Acute closure (%) 8 (2.5) 2 (0.1) , 0.001
Stent thrombosis (%) 2 (0.6) 3 (0.2) NS
Persistent chest pain postprocedure (%) 38 (12.1) 31 (2.3) , 0.001
*In 32% of patients, more than one complication occurred.
NHLBI 5 National Heart, Lung, and Blood Institute.
Table 3. Multivariate Predictors of CK-MB Elevation
Variables Odds Ratio 95% CI p Value
Female gender 1.02 0.92–1.11 0.8
CCS angina class III–IV 1.48 1.08–2.46 0.01
Beta-blocker therapy 0.71 0.58–0.92 0.001
Abciximab use 1.07 0.86–1.11 0.2
Multivessel disease 1.31 1.09–1.82 0.04
Systemic atherosclerosis 1.89 1.29–2.21 0.002
Diffuse coronary disease 1.41 1.09–1.98 0.02
ACC/AHA type C lesion 1.83 1.08–3.68 0.01
LAD vessel intervention 1.01 0.86–1.14 0.2
SVG intervention 2.21 1.12–4.11 0.0001
Stent use 1.26 0.98–1.84 0.04
PRCA use 1.04 0.92–1.26 0.1
ACC/AHA 5 American College of Cardiology/American Heart Association;
CCS 5 Canadian Cardiovascular Society; CI 5 confidence internal; LAD 5 left
anterior descending artery; PRCA 5 percutaneous rotational coronary atherectomy;
SVG 5 saphenous vein graft.
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DISCUSSION
Many studies have established that CK-MB elevation is
more specific and sensitive for myocardial damage rather
than total creatine phosphokinase elevation after MI and
coronary intervention (22–25). The CK-MB isoenzyme
could be released either from myocardial necrosis or pro-
found ischemic injury with retention of cell viability (23).
Several reports have shown that CK-MB elevation follow-
ing coronary intervention is associated with higher late
cardiac events of MI and death (7–10,26–28). Most of these
data were in the era of PTCA. The CK-MB elevation
during coronary interventional procedure is device depen-
dent, and enzyme release is higher for nonballoon devices
(11,29–31). Recent trials with newer devices have shown a
higher incidence of CK-MB release with otherwise success-
ful coronary interventions (12,32). The cause of CK-MB
enzyme release is multifactorial and includes transient
abrupt vessel closure, dissection, spasm, slow flow, distal
thromboembolization, side branch closure, prolonged isch-
emia due to balloon inflation or prolonged hypotension
(5,10,18,26,33,34). Side branch closure was the most fre-
quent procedural complication noted in the CK-MB-
elevation group and was significantly higher after stent use
and in thrombotic lesions (5,35). Despite numerous minor
procedural adverse events, CK-MB elevation has been
shown to occur even in the absence of discernable compli-
cations. In the present study, procedural complications,
prolonged/recurrent chest pain or ECG changes were ob-
served in only 49% of cases with CK-MB elevation. In the
remaining patients, CK-MB elevation was unsuspected and
could not have been predicted after the procedure.
Correlation of CK-MB with new devices and survival.
In our study, CK-MB elevation was seen in 18.7% of
procedures, which is similar to other published studies
(5,7,10,27). Like other studies, CK-MB elevation was
higher after nonballoon devices. In a report by Abdelmeguid
et al. (10), minor CK-MB elevation in 4,484 patients at a
mean follow-up of 36 6 22 months had a worse long-term
prognosis, but most of these patients underwent PTCA or
directional coronary atherectomy. Ghazzal et al. (27) in a
large study reported that CK-MB elevation post-PTCA
had a negative influence on survival, but only in patients
with SVG interventions. Numerous recent studies of
CK-MB elevation postprocedure involving new devices
have reported a lack of correlation of CK-MB release on
survival. Kugelmass et al. (11), using DCA and stents,
reported CK-MB elevation in 64 of 558 patients (11.5%),
and patients with low-to-medium CK-MB elevation had
benign event-free survival on follow-up but in-hospital
adverse events were not mentioned.
Similarly, Cutlip et al. (12) examined three randomized
multicenter trials Balloon vs. Optional Atherectomy Trial
(BOAT), STent Anti-thrombotic Regimen Study
(STARS), Study to Determine Rotablator and Translumi-
nal Angioplasty Strategy (STRATAS) of new devices in-
volving 3,387 patients and reported the lack of association
of CK-MB elevation and mortality at a mean follow-up of
15 6 5 months. The lack of correlation of CK-MB
elevation with mortality after new-device intervention de-
spite its higher incidence as reported in the present study
may be explained on the basis of achieving a stable large
lumen, resulting in lower in-hospital events (’1% major
complications) and possible lower repeat revascularization.
This is in accordance with studies reporting that a large
postprocedure lumen independently correlates with better
prognosis (11,30). Long-term data (three to five years) of
present cohort and other studies will be required to establish
convincingly the observed lack of correlation between mor-
tality and low-to-medium CK-MB elevation after new
devices. Also, it is possible that CK-MB elevation in this
setting may represent ischemic injury with retention of cell
viability rather than true myocardial necrosis (36). This is
supported by the fact that in our study 18 of the 25 patients
with .5 times CK-MB elevations and a pre- and postpro-
cedure analysis of LV function revealed no significant
decline (.5%) in LVEF. Moreover, patients with low-to-
medium CK-MB elevation had no higher in-hospital ad-
verse cardiac events compared with normal CK-MB pa-
tients.
CK-MB elevation after rotational atherectomy. Rota-
tional atherectomy has traditionally been implicated in
CK-MB elevation postprocedure. Our center performs
Table 4. In-Hospital Course and Adverse Cardiac Events in all Patients
Variables
CK-MB >53
(n 5 40)
CK-MB 3–53
(n 5 59)
CK-MB 1–33
(n 5 214)
Normal CK-MB
(n 5 1,362)
Persistent/recurrent chest pain (%) 23 (57.5)† 7 (11.9) 19 (8.9) 122 (8.9)
ECG changes (%) 38 (95)† 43 (72.8)‡ 69 (32.2) 86 (6.3)
Arrhythmia (%) 8 (20)† 1 (1.7) 5 (2.3) 28 (2)
Repeat cardiac catheterization (%) 14 (35)† 5 (8.5) 15 (7) 89 (6.5)
Repeat intervention (%) 7 (17.5)† 1 (1.7) 5 (2.3) 8 (0.6)
CHF (%) 14 (35)† 4 (6.8) 15 (7) 78 (5.7)
Hospital stay postprocedure, days* 5.8 6 3.1† 2.8 6 1.3 2.9 6 1.1 2.6 6 1.5
CHF 5 congestive heart failure; ECG 5 electrocardiogram.
*For patients after first four months of study. †p , 0.001 compared to other groups. ‡p , 0.01 compared to 1–33 elevation and normal CK-MB group.
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PRCA in a high percentage of interventions (’50%), and
CK-MB elevation after PRCA (by univariate analysis only)
was slightly higher than PTCA but lower than stent alone
(35). This probably is attributed to technical advances in
PRCA like slow burr advancement, short ablation runs,
multiple burr approach and avoidance of hypotension dur-
ing ablation (37).
CK-MB elevation and need for in-hospital monitoring.
In most of the previous studies, prolonged postprocedure
hospital stay for observation and monitoring until CK-MB
reached baseline was done and thereby increased the cost of
intervention (7,11,28). Califf et al. (5) have suggested that
patients with elevated CK-MB of 33 normal after inter-
vention should be managed like noninterventional, non-Q-
wave MI patients. In our study, stable patients with low-
to-medium CK-MB elevation were routinely discharged
once CK-MB started declining and not necessarily returned
to baseline without any apparent short-term adverse events.
Therefore, prolonged hospital stay of low-to-medium
CK-MB elevation patients may not be necessary and may
result in significant cost savings.
Multivariate predictors of CK-MB elevation. Diffuse
coronary disease, multivessel disease and systemic athero-
sclerosis correlated independently with CK-MB release.
These data suggest that CK-MB elevation postprocedure
may be a marker for diffuse atherosclerosis and thus might
explain adverse prognosis as seen in some studies (9,10).
Another important variable was stent use, perhaps due to a
higher incidence of side branch occlusion in this group and
distal microembolization of atheromatous debris by high-
pressure balloon inflation (13,35). Our data are consistent
with earlier studies reporting SVG intervention, unstable
angina, ACC/AHA type C lesion and stent use correlating
with CK-MB release (8–13). In the randomized trials, use
of glycoprotein IIb/IIIa inhibitors have been shown to
reduce CK-MB release, which was not observed in our
study largely because of selective use of abciximab in
high-risk coronary lesions (38,39).
One unique observation noted in our study was a protec-
tive effect of beta-blocker therapy at the time of intervention
on CK-MB release as well a lower mortality at midterm
follow-up. To our knowledge, this is the first report of the
protective effects of beta-blocker therapy on CK-MB release
after coronary intervention, and it may be explained largely
on the basis of decreasing myocardial oxygen demand
during intervention.
Study limitations. The present study needs to be inter-
preted with the following limitations. Only two sets of
CK-MB values were routinely measured postprocedure, and
it is possible that in some cases CK-MB might be elevated
after 24 h of interventions. The number of patients dis-
charged with declining but elevated CK-MB values are
relatively small (n 5 162) and a large cohort would be
preferable. Some patients on beta-blocker therapy did not
take beta-blockers on the day of procedure but were
nevertheless included for our analysis. Microembolization
during intervention was not ruled out by any perfusion or
physiologic flow studies. Although lesion length was mea-
sured visually with use of an on-line digital caliper in
questionable cases, it is unlikely to bias our results as
classification of focal versus diffuse coronary disease was
done during the procedure before any postprocedure
CK-MB values were obtained. Troponin, a more sensitive
marker of myocardial necrosis, was not measured in the
present study because of its unavailability at our center until
July 1998 (40). Another important limitation of the present
study is duration of follow-up (13 6 3 months), and it is
possible that mortality curves between CK-MB elevation
and normal CK-MB groups may diverge after three years of
follow-up. However, long-term follow-up of these patients
is ongoing.
Conclusions and study implications. The present study
shows a close association between markers of diffuse coro-
nary atherosclerosis and CK-MB elevation after otherwise
successful coronary intervention as well as lack of an
apparent adverse effect of low-to-medium CK-MB eleva-
tion on in-hospital course and midterm survival. Our data
suggest that early discharge of uncomplicated CK-MB-
elevation (1–53 normal) patients despite elevated values is
safe and may be cost-effective. The effect of CK-MB
elevation after nonballoon devices on long-term follow-up
requires further evaluation. Finally, a randomized trial of
preintervention beta-blocker use to prevent CK-MB eleva-
tion after percutaneous coronary intervention may be war-
ranted.
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